Redsieway drug company responds to patent battle: application for coronavirus three years ago

In response to the research drug Remdesivir for the new coronavirus clinical trials and patent applications, Redsiewe research and development company Gilead On February 8 through weChat public number “Gilead Science” (certified subject: Gilead (Shanghai) Pharmaceutical Technology Co., Ltd.) to respond centrally.

Two clinical trials of Redcywe for the treatment of new coronary pneumonia are under way. Two clinical trials, led by Chinese researchers, are being conducted in Wuhan, and lead research units are expected to release more details in the near future, Gilead said.

Gilead said that while it has not yet been determined whether the drug can safely and effectively treat the new coronavirus infection, given the urgency of the current situation, a variety of measures are being taken to speed up production and increase supply.

In addition, in response to a patent filed by researchers at Wuhan Virus Institute for Ridsey’s use of a new coronavirus, Gilead said gilead developed Ridsyway and has patents in the United States, China and other parts of the world. In 2016, Gilead filed more patents in China and around the world for Ridsiewe’s use of coronaviruses. In China, patent applications for coronavirus applications have yet to be approved.

It said Gilead had no right to interfere with whether the patent office granted patents to Chinese researchers. The patent application from the Wuhan Virus Research Institute was filed more than three years after Gilead filed the application, and consideration of the application will combine current knowledge of the synthetic drug and the patent being filed.

The full text is as follows:

Redsieway drug company responds to patent battle: application for coronavirus three years ago